| Ident. | Authors (with country if any) | Title |
|---|
| 000841 (2019) |
S Ren Andreas Just [Danemark] ; Christian Nielsen [Danemark] ; Jens Christian Werlinrud [Danemark] ; Pia Veldt Larsen [Danemark] ; Camilla Schufri Klinkby [Danemark] ; Henrik Daa Schr Der [Danemark] ; Fran Humby [Royaume-Uni] ; Trine Torfing [Danemark] ; Hanne Lindegaard [Danemark] | Six-month prospective trial in early and long-standing rheumatoid arthritis: evaluating disease activity in the wrist through sequential synovial histopathological analysis, RAMRIS magnetic resonance score and EULAR-OMERACT ultrasound score |
| 000913 (2019) |
Carlotta Nannini [Italie] ; Laura Niccoli [Italie] ; Stelvio Sestini [Italie] ; Iashar Laghai [Italie] ; Angela Coppola [Italie] ; Fabrizio Cantini [Oman] | Remission maintenance after tocilizumab dose-tapering and interruption in patients with giant cell arteritis: an open-label, 18-month, prospective, pilot study. |
| 001015 (2019) |
Ulrika Bergsten ; Katarina Almehed ; Amir Baigi ; Lennart T. H. Jacobsson | A randomized study comparing regular care with a nurse‐led clinic based on tight disease activity control and person‐centred care in patients with rheumatoid arthritis with moderate/high disease activity: A 6‐month evaluation |
| 001172 (2018) |
Marina Mesquida [Espagne] ; Blanca Molins [Espagne] ; Victor Llorenç [Espagne] ; María V. Hernández [Espagne] ; Gerard Espinosa [Espagne] ; Maite Sainz De La Maza [Espagne] ; Alfredo Adán [Espagne] | TWENTY-FOUR MONTH FOLLOW-UP OF TOCILIZUMAB THERAPY FOR REFRACTORY UVEITIS-RELATED MACULAR EDEMA. |
| 001237 (2018) |
Boulos Haraoui [Canada] ; Shahin Jamal [Canada] ; Vandana Ahluwalia [Canada] ; Diana Fung [Canada] ; Tarang Manchanda [Canada] ; Majed Khraishi [Canada] | Real-World Tocilizumab Use in Patients with Rheumatoid Arthritis in Canada: 12-Month Results From an Observational, Noninterventional Study. |
| 001697 (2017) |
Rieke Alten [Allemagne] ; Xavier Mariette [France] ; Hanns-Martin Lorenz [Allemagne] ; Mauro Galeazzi [Italie] ; Alain Cantagrel [France] ; Hubert G. Nü Lein [Allemagne] ; Melanie Chartier [France] ; Yedid Elbez [France] ; Christiane Rauch [Allemagne] ; Manuela Le Bars [France] | Real-world predictors of 12–month intravenous abatacept retention in patients with rheumatoid arthritis in the ACTION observational study |
| 001706 (2017) |
Jennifer Corny | Program to Manage New and Expensive Drugs in Pediatrics: Profile of a New Drug Policy and a 12-Month Descriptive Study |
| 001715 (2017) |
Yasir Jamal Sepah [États-Unis] ; Mohammad Ali Sadiq [États-Unis] ; David S. Chu [États-Unis] ; Mark Dacey [États-Unis] ; Ron Gallemore [États-Unis] ; Pouya Dayani [États-Unis] ; Mostafa Hanout [États-Unis] ; Muhammad Hassan [États-Unis] ; Rubbia Afridi [États-Unis] ; Aniruddha Agarwal [États-Unis] ; Muhammad Sohail Halim [États-Unis] ; Diana V. Do [États-Unis] ; Quan Dong Nguyen [États-Unis] | Primary (Month-6) Outcomes of the STOP-Uveitis Study: Evaluating the Safety, Tolerability, and Efficacy of Tocilizumab in Patients With Noninfectious Uveitis. |
| 001763 (2017) |
Richard Conway [Oman] ; Carl Orr [Irlande (pays)] ; Geraldine M. Mccarthy [Irlande (pays)] | Lesson of the month 1: Septic arthritis with normal acute phase reactants and white cell count in a patient receiving tocilizumab. |
| 001E83 (2015) |
Sella Aarrestad Provan [Norvège] ; Inger Jorid Berg [Norvège] ; Hilde Berner Hammer [Norvège] ; Alexander Mathiessen [Norvège] ; Tore Kristian Kvien [Norvège] ; Anne Grete Semb [Norvège] | The Impact of Newer Biological Disease Modifying Anti-Rheumatic Drugs on Cardiovascular Risk Factors: A 12-Month Longitudinal Study in Rheumatoid Arthritis Patients Treated with Rituximab, Abatacept and Tociliziumab. |
| 002365 (2014) |
Hubert G. Nü Lein [Allemagne] ; Rieke Alten [Allemagne] ; Mauro Galeazzi [Italie] ; Hanns-Martin Lorenz [Allemagne] ; Dimitrios Boumpas [Grèce] ; Michael T. Nurmohamed [Pays-Bas] ; William G. Bensen [Canada] ; Gerd R. Burmester [Allemagne] ; Hans-Hartmut Peter [Allemagne] ; Franz Rainer [Autriche] ; Karel Pavelka [République tchèque] ; Melanie Chartier [France] ; Coralie Poncet [France] ; Christiane Rauch [Allemagne] ; Manuela Le Bars [France] | Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION study |
| 002438 (2014) |
Paul Emery [Royaume-Uni] ; Gerd R. Burmester [Allemagne] ; Vivian P. Bykerk [États-Unis] ; Bernard G. Combe [France] ; Daniel E. Furst [États-Unis] ; Emilie Barré [Belgique] ; Chetan S. Karyekar [États-Unis] ; Dennis A. Wong [États-Unis] ; Tom W J. Huizinga [Pays-Bas] | Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period |
| 002958 (2013) |
J. Kuemmerle-Deschner [Allemagne] ; P. Hawkins [Royaume-Uni] ; H. Hoffman [États-Unis] ; T. Van Der Poll [Pays-Bas] ; U. Walker [Suisse] ; H. Tilson [États-Unis] | THU0392 Beta-confident-registry: Efficacy and safety of canakinumab in cryopyrin associated periodic syndrome - 18 month follow-up |
| 002998 (2013) |
C. C. Mok [Hong Kong] ; P. T. Chan [Hong Kong] ; L. Y. Ho [Hong Kong] ; C. H. To [Hong Kong] | THU0274 Combination of Mycophenolate Mofetil and Tacrolimus for Refractory Lupus Nephritis: A 12-Month Open-Labeled Trial |
| 002B96 (2013) |
M. Khraishi ; R. Aslanov [Canada] ; K. Doyle [Canada] | SAT0055 18-Month Cardiovascular Risk Assessment in Rheumatoid Arthritis (RA) Patients Treated by Biologic Response Modifiers |
| 002F76 (2013) |
M. G. Alpigiani ; P. Salvati ; S. Rosina ; S. Callegari ; G. Tripodi ; R. Lorini ; M. B. Michelis [Italie] ; S. Boero [Italie] | AB1171 Use of bone marrow cells (BMCS) added to platelet-rich plasma (PRP) for treatment of bone degenerative processes in jia patient: 18-month follow-up |
| 003090 (2013) |
P. Ostojic ; N. Damjanov ; A. Dimic ; D. Stefanovic ; M. Lazarevic ; T. Ilic [Serbie] ; S. Zivojinovic | AB0566 Improved efficacy of rituximab in rheumatoid arthritis when administered regularly at six-month intervals – data from the serbian registry (NARASS) |
| 003123 (2013) |
H. Nü Lein ; R. Alten [Allemagne] ; M. Galeazzi [Italie] ; H. M. Lorenz [Allemagne] ; D. Boumpas [Grèce] ; M. T. Nurmohamed [Pays-Bas] ; W. G. Bensen [Canada] ; G. R. Burmester [Allemagne] ; H. H. Peter [Allemagne] ; F. Rainer [Autriche] ; K. Pavelka [République tchèque] ; M. Chartier ; C. Poncet [France] ; C. Rauch [Allemagne] ; M. Le Bars [France] | AB0532 Effect of prior therapy on the efficacy and safety of abatacept: 6-month analysis of the action study |
| 003124 (2013) |
H. Nü Lein ; R. Alten [Allemagne] ; M. Galeazzi [Italie] ; H. M. Lorenz [Allemagne] ; D. Boumpas [Grèce] ; M. T. Nurmohamed [Pays-Bas] ; W. G. Bensen [Canada] ; G. R. Burmester [Allemagne] ; H. H. Peter [Allemagne] ; F. Rainer [Autriche] ; K. Pavelka [République tchèque] ; M. Chartier ; C. Poncet [France] ; C. Rauch [Allemagne] ; M. Le Bars [France] | AB0531 Real-world efficacy and safety of abatacept treatment for RA: 12-month interim analysis of the action study |
| 003205 (2013) |
M. Herly ; K. Stengaard-Pedersen ; P. Vestergaard ; J. P Denphandt [Danemark] ; M. Stergaard [Danemark] ; P. Junker [Danemark] ; M. L. Hetland [Danemark] ; K. H Rslev-Petersen [Danemark] ; T. Ellingsen | AB0316 Patient’s global assessment of general health by vas at baseline predicts ACR/EULAR remission after 3, 6 and 12 month’s of efficient treatment in DMARD- and steroid naÏve early rheumatoid arthritis patients. The danish cimestra-study |
| 003226 (2013) |
M. Boers [Pays-Bas] ; Y. Brault [France] ; I. Logeart [France] ; M. Dougados [France] | AB0306 The influence of the definition of patient global assessment in assessment of ACR/eular remission and minimal disease activity in rheumatoid arthritis: A 3-month cohort study in patients starting etanercept |
